Skip to main
TMDX
TMDX logo

TMDX Stock Forecast & Price Target

TMDX Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 27%
Buy 36%
Hold 36%
Sell 0%
Strong Sell 0%

Bulls say

TransMedics Group Inc. is leveraging its innovative Organ Care System (OCS) to address significant limitations in organ preservation, driving growth in logistics revenue that aligns closely with increases in aviation volume and utilization. The company reported a substantial sequential increase in aviation activity, evidenced by a 12% growth in flight volumes and 11% in flight hours, which supports the assertion that TransMedics is gaining market share. The projected aviation revenue for Q2 is estimated at $29.0 million, marking an approximate 11% quarter-over-quarter increase, further indicating robust financial performance and growth potential in the organ transplant market.

Bears say

TransMedics Group faces significant challenges that could negatively impact its financial performance, particularly related to its reliance on expanding its salesforce and securing new market penetration. The company's future growth hinges on its ability to introduce new products and gain physician mindshare, yet limited commercialization experience indicates potential risks in achieving these objectives. Additionally, the implication of higher aviation penetration suggests a downward pressure on revenue, as it may lead to reduced demand for the Organ Care System and related units.

TMDX has been analyzed by 11 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 36% recommend Buy, 36% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Transmedics Group Inc (TMDX) Forecast

Analysts have given TMDX a Buy based on their latest research and market trends.

According to 11 analysts, TMDX has a Buy consensus rating as of Oct 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $127.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $127.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Transmedics Group Inc (TMDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.